MDM2 and lung carcinoma: Thus, eight case-control studies (6,696 lung cancer cases and 7,972 controls) concerning the associated of the MDM2 SNP309 polymorphism and lung cancer risk were included in this meta-analysis (9–11,17,18,20–22).